Back to mobile site

More on STOK

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-43.1% Growth)
- Ratings (8.2 Score)

Upcoming Events

- Earnings (11/10/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Stoke Therapeutics Inc. (NQ:STOK)
Delayed: 25.68 -0.93 (3.49%)
Prev. Close $26.61  
Open$26.83 
52 Wk High$ 
52 Wk Low$ 
Day High$27.22 
Day Low$25.31 
P/E N/A  
EPS$ 
Volume2,257,814 

Friends, Peers and Foes (?): BIIB, VRTX, ZEAL, ANVS, ARQT (more...)

Oct 21, 2026 04:43 PM Form 144 Stoke Therapeutics, Inc. Filed by: Kaye Edward M. MD
Oct 16, 2026 04:20 PM Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Oct 12, 2026 08:00 AM Stoke Therapeutics shares STK-002 data for eye disorder at AAO
Oct 12, 2026 08:00 AM Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Oct 6, 2026 08:00 AM Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Ann
Oct 5, 2026 07:00 AM Stoke Therapeutics meets with FDA on Dravet syndrome drug NDA
Oct 5, 2026 07:00 AM Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Oct 2, 2026 05:38 PM Form 4 Stoke Therapeutics, Inc. For: Oct 02 Filed by: Allan Jonathan
Oct 2, 2026 05:36 PM Form 4 Stoke Therapeutics, Inc. For: Oct 01 Filed by: Ticho Barry
Oct 2, 2026 04:21 PM Form 144 Stoke Therapeutics, Inc. Filed by: Allan Jonathan
View All Articles

Entities mentioned with STOK

View All Entities